Canaccord Genuity Maintains Buy on Candel Therapeutics, Lowers Price Target to $13

Benzinga · 1d ago
Canaccord Genuity analyst John Newman maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $25 to $13.